The transition from research to translation or application in children is also a place where we could make the same comment about weakness. A major improvement could have been made for RSV infections, but it was blocked because we needed a company to make something special that didn't exist for children. The market is too small, so it was blocked. With specific funding, we could solve the transition and have children-specific treatments that are in the research pipeline but that we cannot apply because of these limitations.
On March 21st, 2023. See this statement in context.